Semaglutide for weight loss
Pro Research Analysisby 
Searched over 200M research papers
Semaglutide for Weight Loss: Efficacy in Obesity and Overweight
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a highly effective medication for weight loss in adults with overweight or obesity, both with and without type 2 diabetes. Multiple clinical trials and systematic reviews have evaluated its impact on body weight, safety, and broader health outcomes.
Weight Loss Outcomes with Semaglutide
Across several large clinical trials, once-weekly subcutaneous semaglutide at a dose of 2.4 mg has consistently resulted in significant weight loss. In the STEP clinical trial program, participants without diabetes experienced mean weight reductions of 14.9% to 17.4% over 68 weeks, with 69% to 79% achieving at least 10% weight loss and 51% to 64% achieving at least 15% weight loss, compared to much lower rates in placebo groups Bergmann2022Wilding2021. Over a two-year period, the STEP 5 trial showed a sustained mean weight loss of 15.2% with semaglutide versus 2.6% with placebo . These results are supported by meta-analyses, which found average weight reductions of around 11.6 kg to 12.3 kg compared to placebo in non-diabetic adults Arastu2022Moiz2024.
Comparison to Other Treatments
Semaglutide has demonstrated superior efficacy compared to other GLP-1 receptor agonists, such as liraglutide. In a head-to-head trial, higher doses of semaglutide (0.2 mg and above) led to greater weight loss (up to 13.8%) than liraglutide (7.8%) over 52 weeks . This advantage, along with its once-weekly dosing, makes semaglutide a more convenient and effective option for many patients Novograd2022Singh2021.
Real-World Effectiveness
Observational studies in clinical practice settings confirm that semaglutide’s weight loss effects are similar to those seen in randomized clinical trials, with patients achieving 5.9% weight loss at 3 months and 10.9% at 6 months . Case reports also highlight substantial weight loss and improvements in mental and physical health with weekly semaglutide plus lifestyle intervention .
Additional Health Benefits
Beyond weight loss, semaglutide treatment has been associated with improvements in cardiometabolic risk factors, such as blood pressure and lipid profiles, as well as enhanced physical function and quality of life Bergmann2022Wilding2021. These benefits are important for reducing the risk of obesity-related diseases.
Safety and Tolerability
The most common side effects of semaglutide are gastrointestinal, including nausea and diarrhea. These are usually mild to moderate and tend to resolve over time. A higher rate of gastrointestinal events is observed compared to placebo, but most do not require discontinuation of treatment Bergmann2022O'Neil2018Garvey2022+2 MORE.
Conclusion
Semaglutide is a highly effective and well-tolerated option for weight loss in adults with overweight or obesity. It leads to substantial, sustained weight reduction and improvements in health markers, outperforming many other available pharmacologic treatments. Its benefits are evident in both clinical trials and real-world practice, making it a valuable tool in the management of obesity Bergmann2022Novograd2022O'Neil2018+7 MORE.
Sources and full results
Most relevant research papers on this topic